| Press Release |
![]() |
| • |
Total revenues for the third quarter 2026 increased 6% to $73.7 billion
|
| • |
Shareholders’ net income for the third quarter 2026 was $1.4 billion, or $5.47 per share
|
| • |
Adjusted income from operations1 for the third quarter 2026 was $2.1 billion, or $7.98 per share
|
| • |
Increasing 2026 outlook for adjusted income from operations1 to at least $30.60 per share2
|
| • |
Hosted 2026 Investor Day, introducing the “Lead to One” vision, setting long-term financial targets, including 10%-14% adjusted EPS CAGR and ~$50B in cumulative operating cash
flow through 2030, and announcing “Accelerate to One” multi-year $3B modernization and productivity initiative
|
|
Consolidated Financial Results (unaudited, dollars in millions):
|
||||||||||||||||
|
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||
|
|
September 30,
|
June 30,
|
September 30,
|
|||||||||||||
|
|
2026
|
2025
|
2026
|
2026
|
||||||||||||
|
Total Revenues
|
$
|
73,683
|
$
|
69,748
|
$
|
71,668
|
$
|
213,845
|
||||||||
|
Net Investment Results from Equity Method Investments3
|
110
|
(178
|
)
|
(110
|
)
|
23
|
||||||||||
|
Adjusted Revenues3
|
$
|
73,793
|
$
|
69,570
|
$
|
71,558
|
$
|
213,868
|
||||||||
|
Consolidated Earnings, net of taxes
|
||||||||||||||||
|
Shareholders’ Net Income
|
$
|
1,442
|
$
|
1,868
|
$
|
1,660
|
$
|
4,756
|
||||||||
|
Net Investment Losses (Gains)1
|
67
|
(43
|
)
|
(55
|
)
|
(221
|
)
|
|||||||||
|
Amortization of Acquired Intangible Assets1
|
449
|
332
|
296
|
1,060
|
||||||||||||
|
Special Items1
|
146
|
(61
|
)
|
153
|
621
|
|||||||||||
|
Adjusted Income from Operations1
|
$
|
2,104
|
$
|
2,096
|
$
|
2,054
|
$
|
6,216
|
||||||||
|
|
||||||||||||||||
|
Shareholders’ Net Income, per share
|
$
|
5.47
|
$
|
6.98
|
$
|
6.29
|
$
|
18.02
|
||||||||
|
Adjusted Income from Operations1, per share
|
$
|
7.98
|
$
|
7.83
|
$
|
7.78
|
$
|
23.55
|
||||||||
| • |
Total revenues for third quarter 2026 increased 6% relative to third quarter 2025,
driven by growth in both Evernorth Health Services and Cigna Healthcare.
|
| • |
Adjusted income from operations1 for third quarter 2026 was stable relative to third quarter 2025, reflecting strong growth in
Cigna Healthcare and Specialty and Care Services, partially offset by lower contribution from Pharmacy Benefit Services.
|
| • |
The SG&A expense ratio4 and adjusted SG&A expense ratio4 were 4.9% and 4.7% for third quarter 2026,
compared to 4.8% and 4.6%, respectively, in third quarter 2025, reflecting investments and initiatives to
support long-term growth, partially offset by operating efficiencies.
|
| • |
The debt-to-capitalization ratio was 41.8% at September 30, 2026 compared to 44.9% at September 30, 2025 and 43.0% at December 31, 2025.
|
| • |
Year to date through November 4, 2026, the Company repurchased 1.8 million shares of common stock for approximately $500 million.
|
|
As of the Periods Ended
|
||||||||||||||||
|
September 30,
|
June 30,
|
December 31,
|
||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Total Pharmacy Customers
|
117,698
|
122,486
|
118,243
|
123,603
|
||||||||||||
|
U.S. Healthcare
|
16,699
|
16,352
|
16,678
|
16,423
|
||||||||||||
|
International Health
|
1,753
|
1,707
|
1,735
|
1,695
|
||||||||||||
|
Total Medical Customers5
|
18,452
|
18,059
|
18,413
|
18,118
|
||||||||||||
|
Behavioral Care
|
23,012
|
23,526
|
27,621
|
28,269
|
||||||||||||
|
Dental
|
18,400
|
18,419
|
18,488
|
18,438
|
||||||||||||
|
Total Customer Relationships
|
177,562
|
182,490
|
182,765
|
188,428
|
||||||||||||
| • |
Total customer relationships at September 30, 2026 decreased 6% from December 31, 2025 to 177.6 million, due to lower pharmacy and behavioral customers.
|
| • |
Total pharmacy customers at September 30, 2026 decreased 5%
from December 31, 2025 to 117.7 million, reflecting expected client transitions and lower
membership from health plan clients.
|
| • |
Total behavioral customers at September 30, 2026 decreased 19% from December 31, 2025 to 23 million, due to the termination of a government contract, with minimal impact to The Cigna Group’s revenues and adjusted income from operations.
|
| • |
Total medical customers5 at September 30, 2026 increased 2% from December 31, 2025 to 18.5 million, reflecting growth in
Middle and Select markets, partially offset by lower membership in National Accounts.
|
|
Financial Results (dollars in millions):
|
||||||||||||||||
|
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||
|
|
September 30,
|
June 30,
|
September 30,
|
|||||||||||||
|
|
2026
|
2025
|
2026
|
2026
|
||||||||||||
|
Total Adjusted Revenues
|
||||||||||||||||
|
Pharmacy Benefit Services
|
$
|
37,276
|
$
|
34,091
|
$
|
34,496
|
$
|
104,774
|
||||||||
|
Specialty and Care Services
|
$
|
26,498
|
$
|
26,300
|
$
|
26,972
|
$
|
78,910
|
||||||||
|
Adjusted Revenues3
|
$
|
63,774
|
$
|
60,391
|
$
|
61,468
|
$
|
183,684
|
||||||||
|
Adjusted Income from Operations, Pre-Tax
|
||||||||||||||||
|
Pharmacy Benefit Services
|
$
|
765
|
$
|
975
|
$
|
609
|
$
|
1,768
|
||||||||
|
Specialty and Care Services
|
$
|
1,064
|
$
|
928
|
$
|
1,054
|
$
|
3,190
|
||||||||
|
Adjusted Income from Operations, Pre-Tax1
|
$
|
1,829
|
$
|
1,903
|
$
|
1,663
|
$
|
4,958
|
||||||||
|
Margin, Pre-Tax6
|
2.9
|
%
|
3.2
|
%
|
2.7
|
%
|
2.7
|
%
|
||||||||
| • |
Evernorth Health Services third quarter 2026
adjusted revenues3 increased 6% and adjusted income from operations, pre-tax1, decreased 4%, relative to third quarter 2025.
|
| • |
For Pharmacy Benefit Services third quarter 2026
relative to third quarter 2025:
|
| ◦ |
Adjusted revenues3 increased 9%, primarily due to drug mix.
|
| ◦ |
Adjusted income from operations, pre-tax1, decreased 22%, primarily reflecting large client contract renewals and strategic investments, consistent with prior commentary.
|
| • |
For Specialty and Care Services third quarter 2026
relative to third quarter 2025:
|
| ◦ |
Adjusted revenues3 increased 1%, reflecting strong specialty distribution revenue growth, partially offset by
lower specialty pharmacy revenue, reflecting higher biosimilar and specialty generic adoption, which lowers costs for clients and patients.
|
| ◦ |
Adjusted income from operations, pre-tax1, increased 15%, primarily reflecting strong organic growth in specialty
businesses, including higher biosimilar and specialty generic adoption.
|
|
Financial Results (dollars in millions):
|
||||||||||||||||
|
|
Three Months Ended
|
Nine Months
Ended
|
||||||||||||||
|
|
September 30,
|
June 30,
|
September 30,
|
|||||||||||||
|
|
2026
|
2025
|
2026
|
2026
|
||||||||||||
|
|
||||||||||||||||
|
Adjusted Revenues3,7
|
$
|
11,708
|
$
|
10,755
|
$
|
11,728
|
$
|
34,913
|
||||||||
|
Adjusted Income from Operations, Pre-Tax1
|
$
|
1,193
|
$
|
1,038
|
$
|
1,276
|
$
|
3,983
|
||||||||
|
Margin, Pre-Tax6
|
10.2
|
%
|
9.7
|
%
|
10.9
|
%
|
11.4
|
%
|
||||||||
| • |
Third quarter 2026 adjusted revenues3 increased 9% relative to third
quarter 2025, primarily reflecting premium rate increases to cover expected increases in
medical costs.
|
| • |
Third quarter 2026 adjusted income from operations, pre-tax1, increased 15% relative to third quarter 2025, primarily due to higher net investment income and improved operating efficiency.
|
| • |
The Cigna Healthcare MCR4 was 85.0% for third
quarter 2026, compared to 84.8% for third quarter 2025, primarily due to U.S. Employer business mix, partially offset by a lower MCR4 within our Individual and Family Plans business.
|
| • |
Cigna Healthcare net medical costs payable8 was $4.86 billion at September 30, 2026, $5.09 billion at June 30, 2026, and $4.53 billion at September 30, 2025. Favorable prior year reserve development on a gross pre-tax basis was $356 million and $319 million for the nine months ended September 30, 2026 and 2025, respectively.
|
|
Financial Results (dollars in millions):
|
||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | June 30, | September 30, | ||||||||||||||
|
2026
|
2025
|
2026
|
2026
|
|||||||||||||
|
Adjusted (Loss) from Operations, Pre-Tax1
|
$
|
(372
|
)
|
$
|
(363
|
)
|
$
|
(389
|
)
|
$
|
(1,138
|
)
|
||||
|
(dollars in millions, except where noted and per share amounts)
|
||
|
2026 Consolidated Metrics
|
Projection for Full Year Ending
December 31, 2026
|
Change from Prior
Projection
|
|
Adjusted Income from Operations, per share1,2
|
at least $30.60
|
+$0.15
|
|
Evernorth Adjusted Income from Operations, Pre-Tax1,2
|
at least $6,900
|
|
|
Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2
|
at least $4,600
|
+$50
|
|
Cigna Healthcare Medical Care Ratio2,4
|
84.2% +/- 25 bps
|
Narrowed by 50 bps
|
|
1.
|
Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it
presents the underlying results of operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’
net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The
Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not
representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment
results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income. See Exhibit 1 for a
reconciliation of consolidated adjusted income from operations to shareholders’ net income.
|
| 2. |
Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income on a forward-looking basis because it is unable to predict,
without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond The Cigna Group’s
control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.
|
| 3. |
Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues
excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that
management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future
underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of
consolidated adjusted revenues to total revenues.
|
| 4. |
Operating ratios are defined as follows:
|
| • |
The Cigna Healthcare medical care ratio (“MCR”) represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or
experience-rated funding arrangements. Changes in percentages may be expressed in basis points (“bps”).
|
| • |
SG&A expense ratio on a GAAP basis for the third quarter 2026 represents enterprise selling, general and administrative expenses of $3,612 million as a percentage of total revenue of $73.7 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the third
quarter 2025 represents enterprise selling, general and administrative expenses of $3,362 million
as a percentage of total revenue of $69.7 billion at a consolidated level.
|
| • |
Adjusted SG&A expense ratio for the third quarter 2026 represents enterprise selling, general and administrative expenses of $3,443 million excluding special items of $169 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the third quarter 2025 represents enterprise selling, general and administrative expenses of $3,191 million excluding special items of $171 million as a percentage of adjusted revenue at a consolidated level.
|
| 5. |
Customer relationships are defined as follows:
|
| • |
Total medical customers includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy, managed care
arrangement, or administrative services agreement issued by Cigna Healthcare; (ii) have access to Cigna Healthcare’s provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna
Healthcare.
|
| 6. |
Margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.
|
| 7. |
The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include the Company’s share
of the joint ventures’ earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.
|
| 8. |
Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other
recoverables. The gross medical costs payable balance was $4.99 billion as of September 30, 2026,
$5.23 billion as of June 30, 2026, and $4.68 billion as of September 30, 2025.
|
|
THE CIGNA GROUP
|
Exhibit 1
|
|
COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)
|
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
Three Months
Ended
June 30, |
||||||||||||||||||
|
(Dollars in millions, except per share amounts)
|
2026
|
2025
|
2026
|
2025
|
2026
|
|||||||||||||||
|
REVENUES
|
||||||||||||||||||||
|
Pharmacy revenues
|
$
|
58,982
|
$
|
56,054
|
$
|
170,191
|
$
|
158,336
|
$
|
57,172
|
||||||||||
|
Premiums
|
9,885
|
9,081
|
29,556
|
30,973
|
9,859
|
|||||||||||||||
|
Fees and other revenues
|
4,529
|
4,380
|
13,337
|
12,412
|
4,365
|
|||||||||||||||
|
Net investment income
|
287
|
233
|
761
|
707
|
272
|
|||||||||||||||
|
Total revenues
|
73,683
|
69,748
|
213,845
|
202,428
|
71,668
|
|||||||||||||||
|
Net investment results from certain equity method investments
|
110
|
(178
|
)
|
23
|
(272
|
)
|
(110
|
)
|
||||||||||||
|
Adjusted revenues (1)
|
$
|
73,793
|
$
|
69,570
|
$
|
213,868
|
$
|
202,156
|
$
|
71,558
|
||||||||||
|
Shareholders’ net income
|
$
|
1,442
|
$
|
1,868
|
$
|
4,756
|
$
|
4,723
|
$
|
1,660
|
||||||||||
|
Pre-tax adjusted income (loss) from operations by segment
|
||||||||||||||||||||
|
Evernorth Health Services
|
$
|
1,829
|
$
|
1,903
|
$
|
4,958
|
$
|
5,033
|
$
|
1,663
|
||||||||||
|
Cigna Healthcare
|
1,193
|
1,038
|
3,983
|
3,419
|
1,276
|
|||||||||||||||
|
Corporate and Other Operations
|
(372
|
)
|
(363
|
)
|
(1,138
|
)
|
(1,131
|
)
|
(389
|
)
|
||||||||||
|
Adjusted income tax expense
|
(546
|
)
|
(482
|
)
|
(1,587
|
)
|
(1,455
|
)
|
(496
|
)
|
||||||||||
|
Consolidated after-tax adjusted income from operations
|
$
|
2,104
|
$
|
2,096
|
$
|
6,216
|
$
|
5,866
|
$
|
2,054
|
||||||||||
|
Weighted average shares (in thousands)
|
263,788
|
267,530
|
263,923
|
269,527
|
263,962
|
|||||||||||||||
|
Common shares outstanding (in thousands)
|
263,403
|
267,072
|
264,154
|
|||||||||||||||||
|
SHAREHOLDERS’ EQUITY at September 30,
|
$
|
43,383
|
$
|
41,805
|
||||||||||||||||
|
SHAREHOLDERS’ EQUITY PER SHARE at September 30,
|
$
|
164.70
|
$
|
156.53
|
||||||||||||||||
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
Three Months
Ended
June 30,
|
||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | 2026 | ||||||||||||||||||||||||||||||||||||
|
(Dollars in millions, except per share amounts)
|
Pre-tax
|
After-tax
|
Pre-tax
|
After-tax
|
Pre-tax
|
After-tax
|
Pre-tax
|
After-tax
|
Pre-tax
|
After-tax
|
||||||||||||||||||||||||||||||
|
SHAREHOLDERS’ NET INCOME
|
||||||||||||||||||||||||||||||||||||||||
|
Shareholders’ net income
|
$
|
1,442
|
$
|
1,868
|
$
|
4,756
|
$
|
4,723
|
$
|
1,660
|
||||||||||||||||||||||||||||||
|
Adjustments to reconcile to adjusted income from operations
|
||||||||||||||||||||||||||||||||||||||||
|
Net investment losses (gains) (2)
|
$
|
74
|
67
|
$
|
(204
|
)
|
(43
|
)
|
$
|
(202
|
)
|
(221
|
)
|
$
|
(348
|
)
|
(194
|
)
|
$
|
(41
|
)
|
(55
|
)
|
|||||||||||||||||
|
Amortization of acquired intangible assets
|
589
|
449
|
436
|
332
|
1,368
|
1,060
|
1,280
|
998
|
389
|
296
|
||||||||||||||||||||||||||||||
|
Special Items
|
||||||||||||||||||||||||||||||||||||||||
|
Strategic optimization program
|
85
|
62
|
222
|
168
|
535
|
405
|
566
|
429
|
70
|
53
|
||||||||||||||||||||||||||||||
|
Charges (benefits) associated with litigation matters
|
60
|
49
|
(17
|
)
|
(13
|
)
|
126
|
101
|
(17
|
)
|
(13
|
)
|
77
|
60
|
||||||||||||||||||||||||||
|
Integration and transaction-related costs
|
23
|
17
|
7
|
6
|
92
|
70
|
297
|
226
|
34
|
26
|
||||||||||||||||||||||||||||||
|
Deferred tax expenses, net
|
—
|
18
|
—
|
19
|
—
|
51
|
—
|
53
|
—
|
17
|
||||||||||||||||||||||||||||||
|
(Gain) on sale of businesses
|
—
|
—
|
(38
|
)
|
(241
|
)
|
(6
|
)
|
(6
|
)
|
(79
|
)
|
(356
|
)
|
(6
|
)
|
(3
|
)
|
||||||||||||||||||||||
|
Adjusted income from operations (3)
|
$
|
2,104
|
$
|
2,096
|
$
|
6,216
|
$
|
5,866
|
$
|
2,054
|
||||||||||||||||||||||||||||||
|
DILUTED EARNINGS PER SHARE
|
||||||||||||||||||||||||||||||||||||||||
|
Shareholders’ net income
|
$
|
5.47
|
$
|
6.98
|
$
|
18.02
|
$
|
17.52
|
$
|
6.29
|
||||||||||||||||||||||||||||||
|
Adjustments to reconcile to adjusted income from operations
|
||||||||||||||||||||||||||||||||||||||||
|
Net investment losses (gains) (2)
|
$
|
0.28
|
0.25
|
$
|
(0.76
|
)
|
(0.16
|
)
|
$
|
(0.77
|
)
|
(0.84
|
)
|
$
|
(1.29
|
)
|
(0.72
|
)
|
$
|
(0.16
|
)
|
(0.21
|
)
|
|||||||||||||||||
|
Amortization of acquired intangible assets
|
2.23
|
1.71
|
1.63
|
1.24
|
5.19
|
4.02
|
4.74
|
3.70
|
1.48
|
1.12
|
||||||||||||||||||||||||||||||
|
Special Items
|
||||||||||||||||||||||||||||||||||||||||
|
Strategic optimization program
|
0.32
|
0.24
|
0.82
|
0.63
|
2.02
|
1.53
|
2.10
|
1.59
|
0.27
|
0.20
|
||||||||||||||||||||||||||||||
|
Charges (benefits) associated with litigation matters
|
0.23
|
0.18
|
(0.06
|
)
|
(0.05
|
)
|
0.48
|
0.38
|
(0.06
|
)
|
(0.05
|
)
|
0.28
|
0.23
|
||||||||||||||||||||||||||
|
Integration and transaction-related costs
|
0.09
|
0.06
|
0.03
|
0.02
|
0.35
|
0.27
|
1.10
|
0.84
|
0.13
|
0.10
|
||||||||||||||||||||||||||||||
|
Deferred tax expenses, net
|
—
|
0.07
|
—
|
0.07
|
—
|
0.19
|
—
|
0.20
|
—
|
0.06
|
||||||||||||||||||||||||||||||
|
(Gain) on sale of businesses
|
—
|
—
|
(0.14
|
)
|
(0.90
|
)
|
(0.02
|
)
|
(0.02
|
)
|
(0.29
|
)
|
(1.32
|
)
|
(0.02
|
)
|
(0.01
|
)
|
||||||||||||||||||||||
|
Adjusted income from operations (3)
|
$
|
7.98
|
$
|
7.83
|
$
|
23.55
|
$
|
21.76
|
$
|
7.78
|
||||||||||||||||||||||||||||||